Drugs / TTAX01
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03818828 | Feb → Dec 2019 | ulcer of lower limbs | BioTissue Holdings, Inc | Completed | No outcome recorded |
| Phase 2 | NCT03230175 | Oct 2017 → Jan 2019 | chronic ulcer of skin | BioTissue Holdings, Inc | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04450693 | Nov 2020 → Mar 2025 | chronic ulcer of skin | BioTissue Holdings, Inc | Completed | No outcome recorded |
| Phase 3 | NCT04176120 | Jul 2020 → Jan 2024 | chronic ulcer of skin | BioTissue Holdings, Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTAX01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04450693 ↗ |
| Modality | Other / unclassified | “TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue” NCT03818828 ↗ |
| Route | Topical | “TTAX01 will be applied directly to the wound surface” NCT03230175 ↗ |